AbCellera Biologics Inc. (NASDAQ:ABCL) Q4 2023 Earnings Call Transcript February 20, 2024 AbCellera Biologics Inc. misses on earnings expectations. Reported EPS is $-0.17 EPS, expectations were $-0.14. AbCellera Biologics Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon. […]
AbCellera, Everest Medicines partner to discover new antibody therapies pharmaceutical-business-review.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceutical-business-review.com Daily Mail and Mail on Sunday newspapers.
Gilead Sciences, Inc. (NASDAQ:GILD), (ABCL) - AbCellera, Gilead Ink New Multi-Target Antibody Discovery Collaboration benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
The Trianni Mouse®, AbCellera’s technology for generating large databases of human antibodies for drug discovery programs, is granted United States patentVANCOUVER, British Columbia (BUSINESS WIRE) $ABCL AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibod.